By Gina Shaw and David Bronstein
Although USP General Chapter <800> requires closed system drug-transfer devices (CSTDs) for the administration of hazardous antineoplastic drugs and recommends them when compounding hazardous drugs, there are no official guidelines on choosing and implementing the devices.
MARCH 23, 2021